pTau217

• Blood-based detection of tau phosphorylated at threonine 217, enabling minimally invasive assessment of neurodegenerative pathology.
• High specificity and sensitivity in identifying abnormal tau accumulation associated with neurodegenerative processes.
• Correlates with established imaging and cerebrospinal fluid biomarkers, providing a reliable alternative to more invasive diagnostic methods.
• Detectable in early stages of neurodegeneration, allowing for timely intervention and monitoring.
• Quantitative measurement facilitates tracking of disease progression and evaluation of therapeutic responses.
• Validated across diverse cohorts, demonstrating consistent performance in various research settings.
• Compatible with high-throughput platforms, supporting large-scale studies and potential clinical applications.

The p-Tau 217 biomarker assay is designed to quantify the levels of tau protein phosphorylated at threonine 217 in plasma. Phosphorylation at this site is a hallmark of tau pathology, which is implicated in neurodegenerative processes. The assay employs ultrasensitive detection methods to measure p-Tau 217 concentrations, facilitating the identification of abnormal tau accumulation.

This biomarker has demonstrated strong correlations with established imaging techniques and cerebrospinal fluid analyses, offering a less invasive alternative for assessing neurodegenerative pathology. Elevated plasma p-Tau 217 levels have been observed in individuals at early stages of neurodegeneration, underscoring its potential utility in early detection and monitoring.

The quantitative nature of the assay allows for precise tracking of disease progression and evaluation of therapeutic efficacy. Its validation across diverse cohorts and compatibility with high-throughput analytical platforms make it a valuable tool in both research and potential clinical contexts.